Follicular Lymphoma
EMA Accepts Filing for Odronextamab to Address Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Anika Sharma
Regeneron Pharmaceuticals achieved a significant milestone with the European Medicines Agency (EMA) accepting the Marketing Authorization Application (MAA) for odronextamab, ...
Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA
SG Tylor
Source – BeiGene BeiGene has announced that the FDA has accepted a supplemental new drug application (sNDA) for the combination ...
Epcoritamab Shows Promise in Follicular Lymphoma Trial
SG Tylor
Source – Abbvie On 28 June 2023, AbbVie in collaboration with Genmab, disclosede the initial findings of the Phase I/II ...
ASCO 2023: Empowering Responses in Follicular Lymphoma: Epcoritamab Combines with Rituximab and Lenalidomide to Unleash Promising Outcomes
SG Tylor
ABSTRACT NUMBER: 7506 Epcoritamab, a novel bispecific antibody targeting CD3 and CD20, has demonstrated potent T-cell-mediated cytotoxic activity against CD20-positive ...
